You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameReserpine
Accession NumberDB00206  (APRD00472)
TypeSmall Molecule
GroupsApproved
DescriptionAn alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. [PubChem]
Structure
Thumb
Synonyms
(-)-Reserpine
(−)-reserpine
(3beta,16beta,17alpha,18beta,20alpha)-11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester
3,4,5-trimethoxybenzoyl methyl reserpate
Apoplon
Reserpin
Reserpine
Serpalan
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-reserpine Tab 0.25mgtablet.25 mgoralNovopharm Limited1967-12-312005-08-10Canada
Reserpinetablet.1 mg/1oralEon Labs, Inc.1988-03-11Not applicableUs
Reserpinetablet.25 mg/1oralEon Labs, Inc.1988-03-11Not applicableUs
Serpasil 0.25mgtablet0.25 mgoralNovartis Pharmaceuticals Canada Inc1954-12-311999-08-04Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ApoplonNot Available
HiserpiaNot Available
NovoreserpineNot Available
ReserfiaNot Available
SerpalanNot Available
SerpanrayNot Available
SerpasilNot Available
Brand mixtures
NameLabellerIngredients
Hydropres 25 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Hydropres 50 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Ser-AP-ES TabNovartis Pharmaceuticals Canada Inc
SaltsNot Available
Categories
UNII8B1QWR724A
CAS number50-55-5
WeightAverage: 608.6787
Monoisotopic: 608.273380888
Chemical FormulaC33H40N2O9
InChI KeyInChIKey=QEVHRUUCFGRFIF-MDEJGZGSSA-N
InChI
InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1
IUPAC Name
methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4(9),5,7-tetraene-19-carboxylate
SMILES
[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[[email protected]](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as yohimbine alkaloids. These are alkaloids containing the pentacyclic yohimban skeleton. The Yohimbinoid alkaloids contain a carbocyclic ring E arising through C-17 to C-18 bond formation in a corynantheine precursor.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassYohimbine alkaloids
Sub ClassNot Available
Direct ParentYohimbine alkaloids
Alternative Parents
Substituents
  • Yohimbine
  • Corynanthean skeleton
  • Yohimbine alkaloid
  • Pyridoindole
  • Beta-carboline
  • Gallic acid or derivatives
  • P-methoxybenzoic acid or derivatives
  • M-methoxybenzoic acid or derivatives
  • Benzoate ester
  • Indole or derivatives
  • Indole
  • Benzylether
  • Benzoic acid or derivatives
  • Methoxybenzene
  • Phenol ether
  • Benzoyl
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Methyl ester
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFoe the treatment of hypertension
PharmacodynamicsReserpine is an adrenergic blocking agent used to treat mild to moderate hypertension via the disruption of norepinephrine vesicular storage. The antihypertensive actions of Reserpine are a result of its ability to deplete catecholamines from peripheral sympathetic nerve endings. These substances are normally involved in controlling heart rate, force of cardiac contraction and peripheral resistance.
Mechanism of actionReserpine's mechanism of action is through inhibition of the ATP/Mg2+ pump responsible for the sequestering of neurotransmitters into storage vesicles located in the presynaptic neuron. The neurotransmitters that are not sequestered in the storage vesicle are readily metabolized by monoamine oxidase (MAO) causing a reduction in catecholamines.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding62%
MetabolismNot Available
Route of eliminationReserpine is extensively metabolized to inactive compounds. It is slowly excreted via the urine and feces.
Half lifeNot Available
ClearanceNot Available
ToxicityPossible human carcinogen. May cause reproductive harm. ORL-RAT LD50 420 mg/kg; IPR-RAT LD50 44 mg/kg; IVN-RAT LD50 15 mg/kg; ORL-MUS LD50 200 mg/kg; SCU-MUS LD50 52 mg/kg; IPR-RBT LD50 7 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9216
Blood Brain Barrier+0.9257
Caco-2 permeable+0.6549
P-glycoprotein substrateSubstrate0.7928
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.75
Renal organic cation transporterInhibitor0.5194
CYP450 2C9 substrateNon-substrate0.8859
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7065
CYP450 1A2 substrateInhibitor0.8965
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9384
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7062
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9439
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1297 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7505
hERG inhibition (predictor II)Non-inhibitor0.6194
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
  • Eli lilly and co
  • Bowman pharmaceuticals inc
  • Bristol myers squibb co
  • Barr laboratories inc
  • Bell pharmacal corp
  • Cm bundy co
  • Elkins sinn div ah robins co inc
  • Everylife
  • Halsey drug co inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Marshall pharmacal corp
  • Mk laboratories inc
  • Mylan pharmaceuticals inc
  • Pharmavite pharmaceuticals
  • Purepac pharmaceutical co
  • Private formulations inc
  • Rexall drug co
  • Roxane laboratories inc
  • Sandoz inc
  • Solvay pharmaceuticals
  • Tablicaps inc
  • Teva pharmaceuticals usa inc
  • Valeant pharmaceuticals international
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Lannett co inc
  • Panray corp sub ormont drug and chemical co inc
  • Vale chemical co inc
  • Vitarine pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral.25 mg
Tabletoral.1 mg/1
Tabletoral.25 mg/1
Tabletoral
Tabletoral0.25 mg
Prices
Unit descriptionCostUnit
Reserpine 0.25 mg tablet1.52USD tablet
Reserpine 0.1 mg tablet0.83USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point264.5 °CPhysProp
water solubility73 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.2Not Available
pKa6.6MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0113 mg/mLALOGPS
logP4.05ALOGPS
logP3.53ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)16.29ChemAxon
pKa (Strongest Basic)7.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area117.78 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity161.42 m3·mol-1ChemAxon
Polarizability66.05 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.3 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-2943000000-8f7998aa667566277f3fView in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Authors unspecified: Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979 Dec 7;242(23):2562-71. [PubMed:490882 ]
  2. Authors unspecified: Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967 Dec 11;202(11):1028-34. [PubMed:4862069 ]
  3. Authors unspecified: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991 Jun 26;265(24):3255-64. [PubMed:2046107 ]
  4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. Epub 2003 May 14. [PubMed:12748199 ]
  5. Moser M: "Cost containment" in the management of hypertension. Ann Intern Med. 1987 Jul;107(1):107-9. [PubMed:3592424 ]
External Links
ATC CodesC02LA51C02AA52C02LA71C02LA01C02AA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.7 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineReserpine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineReserpine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Reserpine is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Reserpine.
AcebutololReserpine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Reserpine.
AcetaminophenThe serum concentration of Reserpine can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Reserpine is combined with Acetazolamide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Reserpine is combined with Acetyldigitoxin.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Reserpine.
adipiplonThe risk or severity of adverse effects can be increased when Reserpine is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Reserpine.
AfatinibThe serum concentration of Reserpine can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Reserpine is combined with Agomelatine.
AlbendazoleThe serum concentration of Reserpine can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Reserpine.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Reserpine.
AlectinibThe serum concentration of Reserpine can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Reserpine is combined with Alfaxalone.
AlfentanilThe serum concentration of Reserpine can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Reserpine is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Reserpine.
AliskirenReserpine may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Reserpine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Reserpine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Reserpine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Reserpine is combined with Alprazolam.
AlprenololReserpine may increase the hypotensive activities of Alprenolol.
AmantadineThe serum concentration of Reserpine can be increased when it is combined with Amantadine.
AmbrisentanReserpine may increase the hypotensive activities of Ambrisentan.
AmifostineReserpine may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Reserpine is combined with Amiloride.
Aminohippuric acidThe serum concentration of Reserpine can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Reserpine can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Reserpine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Reserpine.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Reserpine.
AmlodipineReserpine may increase the hypotensive activities of Amlodipine.
AmobarbitalAmobarbital may increase the hypotensive activities of Reserpine.
AmobarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Reserpine is combined with Amperozide.
AmphetamineReserpine may decrease the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Reserpine can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Reserpine can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Reserpine is combined with Amyl Nitrite.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Reserpine.
ApraclonidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Apraclonidine.
AripiprazoleAripiprazole may increase the hypotensive activities of Reserpine.
AripiprazoleThe risk or severity of adverse effects can be increased when Reserpine is combined with Aripiprazole.
ArotinololReserpine may increase the hypotensive activities of Arotinolol.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Reserpine.
ArticaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Reserpine is combined with Asenapine.
AstemizoleThe serum concentration of Reserpine can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Reserpine.
AtazanavirThe serum concentration of Reserpine can be increased when it is combined with Atazanavir.
AtenololReserpine may increase the hypotensive activities of Atenolol.
AtorvastatinThe serum concentration of Reserpine can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Reserpine.
AzaperoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Azaperone.
AzelastineReserpine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Reserpine can be increased when it is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Reserpine is combined with Azilsartan medoxomil.
AzithromycinThe serum concentration of Reserpine can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Reserpine is combined with Baclofen.
BarbitalBarbital may increase the hypotensive activities of Reserpine.
BarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Barbital.
BefunololReserpine may increase the hypotensive activities of Befunolol.
BenazeprilReserpine may increase the hypotensive activities of Benazepril.
BendroflumethiazideReserpine may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Reserpine.
BenzocaineThe serum concentration of Reserpine can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Benzocaine.
BenzphetamineReserpine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Reserpine is combined with Benzyl alcohol.
BepridilReserpine may increase the hypotensive activities of Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Reserpine.
BetaxololReserpine may increase the hypotensive activities of Betaxolol.
BethanidineReserpine may increase the hypotensive activities of Bethanidine.
BevantololReserpine may increase the hypotensive activities of Bevantolol.
BimatoprostReserpine may increase the hypotensive activities of Bimatoprost.
BiperidenThe serum concentration of Reserpine can be increased when it is combined with Biperiden.
BisoprololReserpine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Reserpine.
BopindololReserpine may increase the hypotensive activities of Bopindolol.
BosentanReserpine may increase the hypotensive activities of Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Reserpine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Reserpine.
BretyliumReserpine may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Reserpine is combined with Brexpiprazole.
BrimonidineReserpine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Reserpine.
BromazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Reserpine.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Reserpine.
BrompheniramineThe risk or severity of adverse effects can be increased when Reserpine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Reserpine is combined with Brotizolam.
BufuralolReserpine may increase the hypotensive activities of Bufuralol.
BumetanideThe risk or severity of adverse effects can be increased when Reserpine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Bupivacaine.
BupranololReserpine may increase the hypotensive activities of Bupranolol.
BuprenorphineThe serum concentration of Reserpine can be increased when it is combined with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Reserpine is combined with Buprenorphine.
BupropionThe serum concentration of Reserpine can be increased when it is combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Reserpine.
ButabarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Butabarbital.
ButacaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Reserpine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Reserpine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Reserpine is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Reserpine.
CabazitaxelThe serum concentration of Reserpine can be increased when it is combined with Cabazitaxel.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Reserpine.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Reserpine.
CaffeineThe serum concentration of Reserpine can be increased when it is combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Reserpine.
CanagliflozinThe risk or severity of adverse effects can be increased when Reserpine is combined with Canagliflozin.
CandesartanReserpine may increase the hypotensive activities of Candesartan.
CandoxatrilReserpine may increase the hypotensive activities of Candoxatril.
CaptoprilReserpine may increase the hypotensive activities of Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Reserpine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Reserpine is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Reserpine.
CarisoprodolThe risk or severity of adverse effects can be increased when Reserpine is combined with Carisoprodol.
CaroxazoneCaroxazone may increase the hypotensive activities of Reserpine.
CarteololReserpine may increase the hypotensive activities of Carteolol.
CarvedilolReserpine may increase the hypotensive activities of Carvedilol.
CaspofunginThe serum concentration of Reserpine can be increased when it is combined with Caspofungin.
CeliprololReserpine may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Reserpine.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Reserpine.
CetirizineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Reserpine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chloroprocaine.
ChloroquineThe serum concentration of Reserpine can be increased when it is combined with Chloroquine.
ChlorothiazideReserpine may increase the hypotensive activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorphenamine.
ChlorphentermineReserpine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Reserpine.
ChlorpromazineThe serum concentration of Reserpine can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Reserpine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Reserpine can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorprothixene.
ChlorthalidoneReserpine may increase the hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorzoxazone.
CholesterolThe serum concentration of Reserpine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Reserpine can be decreased when it is combined with Cholic Acid.
CilazaprilReserpine may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Reserpine.
CinchocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cinchocaine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Reserpine.
CiprofloxacinThe serum concentration of Reserpine can be increased when it is combined with Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Reserpine.
CitalopramThe risk or severity of adverse effects can be increased when Reserpine is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Reserpine.
ClarithromycinThe serum concentration of Reserpine can be increased when it is combined with Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Reserpine is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Reserpine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Reserpine.
ClofazimineThe serum concentration of Reserpine can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when Reserpine is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Reserpine.
ClomipramineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Clonazepam.
ClonidineReserpine may increase the hypotensive activities of Clonidine.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Reserpine.
ClorazepateThe risk or severity of adverse effects can be increased when Reserpine is combined with Clorazepate.
ClotrimazoleThe serum concentration of Reserpine can be decreased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Reserpine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Reserpine.
CobicistatThe serum concentration of Reserpine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Reserpine.
CocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Reserpine is combined with Codeine.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Reserpine.
ColchicineThe serum concentration of Reserpine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Reserpine can be increased when it is combined with Colforsin.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Reserpine.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Reserpine.
CrizotinibThe serum concentration of Reserpine can be increased when it is combined with Crizotinib.
CryptenamineReserpine may increase the hypotensive activities of Cryptenamine.
CyclizineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Reserpine.
CyclophosphamideThe serum concentration of Reserpine can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Reserpine.
CyclothiazideReserpine may increase the hypotensive activities of Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Reserpine.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Reserpine.
DaclatasvirThe serum concentration of Reserpine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Reserpine.
DactinomycinThe serum concentration of Reserpine can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Reserpine is combined with Dantrolene.
DapagliflozinThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapoxetine.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Reserpine.
DasatinibThe serum concentration of Reserpine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Reserpine.
DebrisoquinReserpine may increase the hypotensive activities of Debrisoquin.
deramciclaneThe risk or severity of adverse effects can be increased when Reserpine is combined with deramciclane.
DeserpidineReserpine may increase the hypotensive activities of Deserpidine.
DesfluraneThe risk or severity of adverse effects can be increased when Reserpine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Reserpine.
DeslanosideThe risk or severity of adverse effects can be increased when Reserpine is combined with Deslanoside.
DesloratadineThe serum concentration of Reserpine can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Reserpine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Reserpine.
DetomidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Detomidine.
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Reserpine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dexmedetomidine.
DextroamphetamineReserpine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Reserpine.
DextromoramideThe risk or severity of adverse effects can be increased when Reserpine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Reserpine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Reserpine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Reserpine.
DiazoxideDiazoxide may increase the hypotensive activities of Reserpine.
DiclofenacThe serum concentration of Reserpine can be increased when it is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Reserpine is combined with Diclofenamide.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Reserpine.
DifenoxinThe risk or severity of adverse effects can be increased when Reserpine is combined with Difenoxin.
DigitoxinThe risk or severity of adverse effects can be increased when Reserpine is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Reserpine is combined with Digoxin.
DigoxinThe serum concentration of Reserpine can be decreased when it is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Reserpine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Reserpine.
DiltiazemReserpine may increase the hypotensive activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Reserpine is combined with Dimenhydrinate.
DinutuximabThe risk or severity of adverse effects can be increased when Reserpine is combined with Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Reserpine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Reserpine is combined with Diphenoxylate.
DipyridamoleThe risk or severity of adverse effects can be increased when Reserpine is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Reserpine.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Reserpine.
DoramectinThe risk or severity of adverse effects can be increased when Reserpine is combined with Doramectin.
DorzolamideReserpine may increase the hypotensive activities of Dorzolamide.
DoxazosinReserpine may increase the hypotensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Reserpine.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Reserpine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
DoxylamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Reserpine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
DronedaroneThe serum concentration of Reserpine can be increased when it is combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Reserpine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Reserpine is combined with Drotebanol.
DuloxetineReserpine may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Reserpine.
DyclonineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Reserpine is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Reserpine.
EfavirenzThe risk or severity of adverse effects can be increased when Reserpine is combined with Efavirenz.
EfonidipineReserpine may increase the hypotensive activities of Efonidipine.
ElbasvirThe serum concentration of Reserpine can be increased when it is combined with Elbasvir.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Reserpine.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Reserpine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Reserpine is combined with Empagliflozin.
EnalaprilReserpine may increase the hypotensive activities of Enalapril.
EnalaprilatReserpine may increase the hypotensive activities of Enalaprilat.
EnfluraneThe risk or severity of adverse effects can be increased when Reserpine is combined with Enflurane.
EntacaponeThe risk or severity of adverse effects can be increased when Reserpine is combined with Entacapone.
EnzalutamideThe serum concentration of Reserpine can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Reserpine.
EplerenoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Eplerenone.
EpoprostenolReserpine may increase the hypotensive activities of Epoprostenol.
EprosartanReserpine may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Reserpine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Reserpine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Reserpine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Reserpine.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Reserpine.
EscitalopramThe risk or severity of adverse effects can be increased when Reserpine is combined with Escitalopram.
EsmololReserpine may increase the hypotensive activities of Esmolol.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Reserpine.
EstazolamThe risk or severity of adverse effects can be increased when Reserpine is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Reserpine.
EstramustineThe serum concentration of Reserpine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Reserpine.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Reserpine.
EszopicloneThe risk or severity of adverse effects can be increased when Reserpine is combined with Eszopiclone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Reserpine is combined with Etacrynic acid.
EthanolReserpine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Reserpine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Reserpine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Reserpine.
EthosuximideThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Reserpine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Reserpine is combined with Etomidate.
EtoperidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Reserpine.
EtoposideThe serum concentration of Reserpine can be increased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etorphine.
EtravirineThe serum concentration of Reserpine can be increased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Reserpine.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Reserpine.
EzogabineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Reserpine is combined with Felbamate.
FelodipineReserpine may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fenfluramine.
FenoldopamReserpine may increase the hypotensive activities of Fenoldopam.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Reserpine.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Reserpine.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Reserpine.
FexofenadineThe serum concentration of Reserpine can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Reserpine.
FidaxomicinThe serum concentration of Reserpine can be increased when it is combined with Fidaxomicin.
FlibanserinThe risk or severity of adverse effects can be increased when Reserpine is combined with Flibanserin.
FluconazoleThe serum concentration of Reserpine can be increased when it is combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Reserpine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluoxetine.
FlupentixolThe serum concentration of Reserpine can be increased when it is combined with Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Reserpine is combined with Flupentixol.
FluphenazineThe serum concentration of Reserpine can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluphenazine.
FlurazepamThe serum concentration of Reserpine can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Reserpine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluvoxamine.
FosinoprilReserpine may increase the hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Reserpine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Reserpine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Reserpine.
FurazolidoneFurazolidone may increase the hypotensive activities of Reserpine.
FurosemideThe risk or severity of adverse effects can be increased when Reserpine is combined with Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Reserpine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Reserpine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Reserpine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Reserpine.
GefitinibThe serum concentration of Reserpine can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Reserpine.
GenisteinThe serum concentration of Reserpine can be increased when it is combined with Genistein.
GlutethimideThe risk or severity of adverse effects can be increased when Reserpine is combined with Glutethimide.
GlyburideThe serum concentration of Reserpine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Reserpine can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Reserpine can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Reserpine.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Reserpine.
GrepafloxacinThe serum concentration of Reserpine can be increased when it is combined with Grepafloxacin.
GuanabenzReserpine may increase the hypotensive activities of Guanabenz.
GuanadrelReserpine may increase the hypotensive activities of Guanadrel.
GuanethidineReserpine may increase the hypotensive activities of Guanethidine.
GuanfacineReserpine may increase the hypotensive activities of Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Halazepam.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Reserpine.
HaloperidolThe serum concentration of Reserpine can be increased when it is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Reserpine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Reserpine is combined with Heroin.
HexamethoniumReserpine may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Reserpine.
HexobarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Hexobarbital.
HydracarbazineHydracarbazine may increase the hypotensive activities of Reserpine.
HydralazineReserpine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideReserpine may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Reserpine.
HydrocortisoneThe serum concentration of Reserpine can be increased when it is combined with Hydrocortisone.
HydroflumethiazideReserpine may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideReserpine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
HydroxyzineThe risk or severity of adverse effects can be increased when Reserpine is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Reserpine.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Reserpine.
IdelalisibThe serum concentration of Reserpine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Iloperidone.
IloprostIloprost may increase the hypotensive activities of Reserpine.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Reserpine.
ImatinibThe serum concentration of Reserpine can be increased when it is combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Reserpine.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Reserpine.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Reserpine.
IndalpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Indalpine.
IndapamideReserpine may increase the hypotensive activities of Indapamide.
IndenololReserpine may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Reserpine can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Reserpine.
IndomethacinThe serum concentration of Reserpine can be increased when it is combined with Indomethacin.
IndoraminReserpine may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Reserpine.
IproniazidIproniazid may increase the hypotensive activities of Reserpine.
IrbesartanReserpine may increase the hypotensive activities of Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Reserpine.
IsavuconazoniumThe serum concentration of Reserpine can be increased when it is combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Reserpine.
IsofluraneThe risk or severity of adverse effects can be increased when Reserpine is combined with Isoflurane.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Reserpine is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Reserpine is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Reserpine is combined with Isoxsuprine.
IsradipineReserpine may increase the hypotensive activities of Isradipine.
ItraconazoleThe serum concentration of Reserpine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Reserpine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Reserpine.
IvermectinThe serum concentration of Reserpine can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Reserpine can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Reserpine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Reserpine.
KetobemidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Reserpine.
KetoconazoleThe serum concentration of Reserpine can be increased when it is combined with Ketoconazole.
LabetalolReserpine may increase the hypotensive activities of Labetalol.
LacidipineReserpine may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Reserpine.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Reserpine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Reserpine.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Reserpine.
LansoprazoleThe serum concentration of Reserpine can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Reserpine can be increased when it is combined with Lapatinib.
LatanoprostReserpine may increase the hypotensive activities of Latanoprost.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Reserpine.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Reserpine.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Reserpine.
LercanidipineReserpine may increase the hypotensive activities of Lercanidipine.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Reserpine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Reserpine.
LevobunololReserpine may increase the hypotensive activities of Levobunolol.
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Reserpine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Reserpine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Reserpine is combined with Levocetirizine.
LevodopaReserpine may increase the orthostatic hypotensive activities of Levodopa.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Reserpine.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Reserpine.
LevofloxacinThe serum concentration of Reserpine can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Reserpine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Reserpine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Reserpine is combined with Levorphanol.
LevothyroxineThe serum concentration of Reserpine can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Reserpine can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Reserpine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Reserpine.
LiothyronineThe serum concentration of Reserpine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Reserpine can be decreased when it is combined with Liotrix.
LisdexamfetamineReserpine may decrease the stimulatory activities of Lisdexamfetamine.
LisinoprilReserpine may increase the hypotensive activities of Lisinopril.
LithiumLithium may increase the neurotoxic activities of Reserpine.
LithiumThe risk or severity of adverse effects can be increased when Reserpine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Reserpine is combined with Lofentanil.
LofexidineReserpine may increase the hypotensive activities of Lofexidine.
LomitapideThe serum concentration of Reserpine can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Reserpine.
LoperamideThe serum concentration of Reserpine can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Reserpine can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Reserpine can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Reserpine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Reserpine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Reserpine.
LosartanReserpine may increase the hypotensive activities of Losartan.
LovastatinThe serum concentration of Reserpine can be increased when it is combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Reserpine is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Reserpine is combined with Lu AA21004.
LumacaftorThe serum concentration of Reserpine can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Lurasidone.
MacitentanReserpine may increase the hypotensive activities of Macitentan.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Reserpine is combined with Magnesium Sulfate.
ManidipineReserpine may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Reserpine is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Reserpine.
MebanazineMebanazine may increase the hypotensive activities of Reserpine.
MebendazoleThe serum concentration of Reserpine can be increased when it is combined with Mebendazole.
MecamylamineReserpine may increase the hypotensive activities of Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Reserpine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Medetomidine.
MefloquineThe serum concentration of Reserpine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Reserpine can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Reserpine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Melperone.
MephentermineReserpine may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mepivacaine.
MeprobamateThe serum concentration of Reserpine can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Reserpine is combined with Meprobamate.
MequitazineReserpine may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Reserpine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Reserpine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Reserpine is combined with Methadyl Acetate.
MethamphetamineReserpine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Reserpine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Reserpine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Reserpine is combined with Methocarbamol.
MethohexitalMethohexital may increase the hypotensive activities of Reserpine.
MethohexitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Methohexital.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Reserpine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Reserpine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Reserpine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Reserpine is combined with Methyclothiazide.
MethyldopaReserpine may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Reserpine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Reserpine.
MethylphenidateThe risk or severity of adverse effects can be increased when Reserpine is combined with Methylphenidate.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Reserpine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Reserpine.
MetipranololReserpine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Reserpine.
MetolazoneReserpine may increase the hypotensive activities of Metolazone.
MetoprololReserpine may increase the hypotensive activities of Metoprolol.
MetyrosineReserpine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Reserpine.
MibefradilReserpine may increase the hypotensive activities of Mibefradil.
MiconazoleThe serum concentration of Reserpine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Reserpine.
MifepristoneThe serum concentration of Reserpine can be decreased when it is combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Reserpine is combined with Milnacipran.
MinaprineMinaprine may increase the hypotensive activities of Reserpine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
MinoxidilReserpine may increase the hypotensive activities of Minoxidil.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Reserpine.
MirtazapineReserpine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Reserpine.
MitomycinThe serum concentration of Reserpine can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Reserpine.
MoclobemideMoclobemide may increase the hypotensive activities of Reserpine.
MoexiprilReserpine may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Molindone.
MolsidomineMolsidomine may increase the hypotensive activities of Reserpine.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Reserpine.
MorphineThe serum concentration of Reserpine can be increased when it is combined with Morphine.
MoxonidineReserpine may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Reserpine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
NabiloneThe risk or severity of adverse effects can be increased when Reserpine is combined with Nabilone.
NadololReserpine may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Reserpine.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Reserpine.
NaltrexoneThe serum concentration of Reserpine can be increased when it is combined with Naltrexone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Reserpine.
NaringeninThe serum concentration of Reserpine can be increased when it is combined with Naringenin.
NebivololReserpine may increase the hypotensive activities of Nebivolol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Reserpine.
NelfinavirThe serum concentration of Reserpine can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Reserpine can be increased when it is combined with Neostigmine.
NesiritideThe risk or severity of adverse effects can be increased when Reserpine is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Reserpine.
NicardipineReserpine may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Reserpine.
NifedipineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nifedipine.
NiguldipineReserpine may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Reserpine.
NilotinibThe serum concentration of Reserpine can be increased when it is combined with Nilotinib.
NilvadipineReserpine may increase the hypotensive activities of Nilvadipine.
NimodipineReserpine may increase the hypotensive activities of Nimodipine.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Reserpine.
NisoldipineReserpine may increase the hypotensive activities of Nisoldipine.
NitrazepamThe serum concentration of Reserpine can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Nitrazepam.
NitrendipineReserpine may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Reserpine is combined with Nitroglycerin.
NitroprussideReserpine may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Reserpine is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Reserpine.
NorethisteroneThe serum concentration of Reserpine can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Reserpine.
ObinutuzumabReserpine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Reserpine.
OlanzapineThe risk or severity of adverse effects can be increased when Reserpine is combined with Olanzapine.
OlmesartanReserpine may increase the hypotensive activities of Olmesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Reserpine is combined with Olopatadine.
OmapatrilatReserpine may increase the hypotensive activities of Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Reserpine.
OmeprazoleThe serum concentration of Reserpine can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Reserpine is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Reserpine is combined with Opium.
OrphenadrineReserpine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Reserpine.
OsanetantThe risk or severity of adverse effects can be increased when Reserpine is combined with Osanetant.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Reserpine.
OuabainThe risk or severity of adverse effects can be increased when Reserpine is combined with Ouabain.
OxazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxazepam.
OxprenololReserpine may increase the hypotensive activities of Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxymorphone.
P-NitrophenolThe serum concentration of Reserpine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Reserpine.
PaclitaxelThe serum concentration of Reserpine can be increased when it is combined with Paclitaxel.
PaliperidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Paliperidone.
Palmitic AcidThe serum concentration of Reserpine can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Reserpine.
PantoprazoleThe serum concentration of Reserpine can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Reserpine is combined with Papaverine.
ParaldehydeReserpine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Reserpine.
PargylineReserpine may increase the hypotensive activities of Pargyline.
ParoxetineThe risk or severity of adverse effects can be increased when Reserpine is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Reserpine.
PenbutololReserpine may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pentazocine.
PentobarbitalPentobarbital may increase the hypotensive activities of Reserpine.
PentobarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Pentobarbital.
PentoliniumReserpine may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Reserpine.
PerampanelThe risk or severity of adverse effects can be increased when Reserpine is combined with Perampanel.
PerindoprilReserpine may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Reserpine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Reserpine.
PhenelzinePhenelzine may increase the hypotensive activities of Reserpine.
PheniprazinePheniprazine may increase the hypotensive activities of Reserpine.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Reserpine.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Reserpine.
PhenoxybenzamineReserpine may increase the hypotensive activities of Phenoxybenzamine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Reserpine is combined with Phenoxyethanol.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Reserpine.
PhentermineReserpine may decrease the stimulatory activities of Phentermine.
PhentolamineReserpine may increase the hypotensive activities of Phentolamine.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Reserpine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Reserpine.
PimozideThe serum concentration of Reserpine can be increased when it is combined with Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Reserpine is combined with Pimozide.
PinacidilReserpine may increase the hypotensive activities of Pinacidil.
PindololReserpine may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pipotiazine.
PirlindolePirlindole may increase the hypotensive activities of Reserpine.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Reserpine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Reserpine.
PizotifenThe risk or severity of adverse effects can be increased when Reserpine is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Reserpine can be decreased when it is combined with Platelet Activating Factor.
PolythiazideReserpine may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Reserpine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Reserpine.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Reserpine.
PonatinibThe serum concentration of Reserpine can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Reserpine can be increased when it is combined with Posaconazole.
PractololReserpine may increase the hypotensive activities of Practolol.
PramipexoleReserpine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Reserpine.
PravastatinThe serum concentration of Reserpine can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Prazepam.
PrazosinReserpine may increase the hypotensive activities of Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Reserpine.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Reserpine.
PrednisoneThe serum concentration of Reserpine can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Reserpine is combined with Pregabalin.
PrilocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Prilocaine.
PrimidonePrimidone may increase the hypotensive activities of Reserpine.
PrimidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Primidone.
ProbenecidThe serum concentration of Reserpine can be increased when it is combined with Probenecid.
ProcaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Reserpine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Reserpine.
PromazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Reserpine.
PropafenoneThe serum concentration of Reserpine can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Reserpine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Propoxycaine.
PropranololReserpine may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Reserpine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Reserpine.
PSD502The risk or severity of adverse effects can be increased when Reserpine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Quazepam.
QuercetinThe serum concentration of Reserpine can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quetiapine.
QuinacrineThe serum concentration of Reserpine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Reserpine.
QuinaprilReserpine may increase the hypotensive activities of Quinapril.
QuinidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quinidine.
QuinidineThe serum concentration of Reserpine can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Reserpine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Reserpine.
RamelteonThe risk or severity of adverse effects can be increased when Reserpine is combined with Ramelteon.
RamiprilRamipril may increase the hypotensive activities of Reserpine.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Reserpine.
RanitidineThe serum concentration of Reserpine can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Reserpine.
RasagilineRasagiline may increase the hypotensive activities of Reserpine.
ReboxetineThe serum concentration of Reserpine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Reserpine can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Reserpine is combined with Remifentanil.
RemikirenReserpine may increase the hypotensive activities of Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Reserpine is combined with Remoxipride.
RescinnamineReserpine may increase the hypotensive activities of Rescinnamine.
RifampicinThe serum concentration of Reserpine can be decreased when it is combined with Rifampicin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Reserpine.
RilpivirineThe serum concentration of Reserpine can be increased when it is combined with Rilpivirine.
RiociguatReserpine may increase the hypotensive activities of Riociguat.
RisperidoneReserpine may increase the hypotensive activities of Risperidone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Reserpine.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Reserpine.
RituximabReserpine may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Reserpine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Reserpine.
RolapitantThe serum concentration of Reserpine can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Reserpine.
RomifidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Romifidine.
RopiniroleReserpine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ropivacaine.
RotigotineReserpine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Reserpine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Reserpine is combined with S-Ethylisothiourea.
SafrazineSafrazine may increase the hypotensive activities of Reserpine.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Reserpine.
SaprisartanReserpine may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Reserpine can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Reserpine can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Reserpine.
SecobarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Reserpine.
SelexipagReserpine may increase the hypotensive activities of Selexipag.
SertindoleThe risk or severity of adverse effects can be increased when Reserpine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Reserpine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Reserpine is combined with Sevoflurane.
SildenafilSildenafil may increase the antihypertensive activities of Reserpine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Reserpine.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Reserpine.
SimeprevirThe serum concentration of Reserpine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Reserpine can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Reserpine can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Reserpine.
SitaxentanReserpine may increase the hypotensive activities of Sitaxentan.
Sodium oxybateThe risk or severity of adverse effects can be increased when Reserpine is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Reserpine.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Reserpine.
SorafenibThe serum concentration of Reserpine can be increased when it is combined with Sorafenib.
SotalolReserpine may increase the hypotensive activities of Sotalol.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Reserpine.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Reserpine.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Reserpine.
SpiraprilReserpine may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Spironolactone.
St. John's WortThe serum concentration of Reserpine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Reserpine can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Reserpine is combined with Stiripentol.
StreptozocinThe serum concentration of Reserpine can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Reserpine is combined with Sufentanil.
SulfinpyrazoneThe serum concentration of Reserpine can be increased when it is combined with Sulfinpyrazone.
SulpirideThe risk or severity of adverse effects can be increased when Reserpine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Reserpine.
SunitinibThe serum concentration of Reserpine can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Reserpine is combined with Suvorexant.
TacrineThe serum concentration of Reserpine can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Reserpine.
TadalafilTadalafil may increase the antihypertensive activities of Reserpine.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Reserpine.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Reserpine.
TasimelteonThe risk or severity of adverse effects can be increased when Reserpine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Reserpine.
Taurocholic AcidThe serum concentration of Reserpine can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Reserpine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Reserpine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Reserpine.
TelmisartanReserpine may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Temazepam.
TemocaprilReserpine may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Reserpine.
TemsirolimusThe serum concentration of Reserpine can be increased when it is combined with Temsirolimus.
TerazosinThe risk or severity of adverse effects can be increased when Reserpine is combined with Terazosin.
TerfenadineThe serum concentration of Reserpine can be increased when it is combined with Terfenadine.
TerlipressinReserpine may increase the hypotensive activities of Terlipressin.
TesmilifeneThe serum concentration of Reserpine can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Reserpine can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetrodotoxin.
ThalidomideReserpine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Reserpine.
ThiamylalThiamylal may increase the hypotensive activities of Reserpine.
ThiamylalThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiamylal.
ThiopentalThiopental may increase the hypotensive activities of Reserpine.
ThiopentalThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tiagabine.
TiboloneReserpine may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Reserpine.
TicagrelorThe serum concentration of Reserpine can be increased when it is combined with Ticagrelor.
TicrynafenReserpine may increase the hypotensive activities of Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tiletamine.
TimololReserpine may increase the hypotensive activities of Timolol.
TizanidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tizanidine.
TolazolineReserpine may increase the hypotensive activities of Tolazoline.
TolcaponeThe risk or severity of adverse effects can be increased when Reserpine is combined with Tolcapone.
ToloxatoneToloxatone may increase the hypotensive activities of Reserpine.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Reserpine.
TolvaptanThe serum concentration of Reserpine can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Reserpine is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Reserpine.
TorasemideReserpine may increase the hypotensive activities of Torasemide.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Reserpine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Reserpine.
TrandolaprilReserpine may increase the hypotensive activities of Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Reserpine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Reserpine.
TranylcypromineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Reserpine.
TravoprostReserpine may increase the hypotensive activities of Travoprost.
TrazodoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Trazodone.
TreprostinilReserpine may increase the hypotensive activities of Treprostinil.
TriamtereneThe risk or severity of adverse effects can be increased when Reserpine is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Reserpine is combined with Triazolam.
TrichlormethiazideReserpine may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineThe serum concentration of Reserpine can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Reserpine can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Triflupromazine.
TrimazosinReserpine may increase the hypotensive activities of Trimazosin.
TrimethaphanReserpine may increase the hypotensive activities of Trimethaphan.
TrimethoprimThe serum concentration of Reserpine can be decreased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Reserpine.
TriprolidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Triprolidine.
TroleandomycinThe serum concentration of Reserpine can be increased when it is combined with Troleandomycin.
UdenafilUdenafil may increase the antihypertensive activities of Reserpine.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Reserpine.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Reserpine.
UnoprostoneReserpine may increase the hypotensive activities of Unoprostone.
Valproic AcidThe risk or severity of adverse effects can be increased when Reserpine is combined with Valproic Acid.
ValsartanValsartan may increase the hypotensive activities of Reserpine.
VardenafilVardenafil may increase the antihypertensive activities of Reserpine.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Reserpine.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Reserpine.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Reserpine.
VerapamilThe risk or severity of adverse effects can be increased when Reserpine is combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Reserpine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Reserpine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Reserpine.
VincristineThe serum concentration of Reserpine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Reserpine can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Reserpine.
VortioxetineThe risk or severity of adverse effects can be increased when Reserpine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Xylazine.
XylometazolineReserpine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Reserpine.
ZaleplonThe risk or severity of adverse effects can be increased when Reserpine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Reserpine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Reserpine.
ZimelidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Zimelidine.
ZimelidineThe serum concentration of Reserpine can be increased when it is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Reserpine.
ZolpidemThe risk or severity of adverse effects can be increased when Reserpine is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Reserpine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Reserpine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Reserpine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Reserpine is combined with Zuclopenthixol.
Food Interactions
  • Magnesium, potassium and zinc needs increased.
  • Take with food to reduce irritation. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.
Gene Name:
SLC18A2
Uniprot ID:
Q05940
Molecular Weight:
55712.075 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sievert MK, Hajipour AR, Ruoho AE: Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels. Anal Biochem. 2007 Aug 1;367(1):68-78. Epub 2007 May 3. [PubMed:17559790 ]
  4. Naudon L, Leroux-Nicollet I, Raisman-Vozari R, Botton D, Costentin J: Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex. Synapse. 1995 Sep;21(1):29-36. [PubMed:8525459 ]
  5. Erickson JD, Eiden LE, Hoffman BJ: Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10993-7. [PubMed:1438304 ]
  6. Mandela P, Chandley M, Xu YY, Zhu MY, Ordway GA: Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles. Neurochem Int. 2010 May-Jun;56(6-7):760-7. doi: 10.1016/j.neuint.2010.02.011. Epub 2010 Feb 20. [PubMed:20176067 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin transmembrane transporter activity
Specific Function:
Involved in the transport of biogenic monoamines, such as serotonin, from the cytoplasm into the secretory vesicles of neuroendocrine and endocrine cells.
Gene Name:
SLC18A1
Uniprot ID:
P54219
Molecular Weight:
56256.71 Da
References
  1. Ashe KM, Chiu WL, Khalifa AM, Nicolas AN, Brown BL, De Martino RR, Alexander CP, Waggener CT, Fischer-Stenger K, Stewart JK: Vesicular monoamine transporter-1 (VMAT-1) mRNA and immunoreactive proteins in mouse brain. Neuro Endocrinol Lett. 2011;32(3):253-8. [PubMed:21712771 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522 ]
  2. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764 ]
  3. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  4. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  5. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945 ]
  6. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153 ]
  7. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  8. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
  9. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H: Drug excretion mediated by a new prototype of polyspecific transporter. Nature. 1994 Dec 8;372(6506):549-52. [PubMed:7990927 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
  2. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermuller N, Schomig E: Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem. 1998 Nov 20;273(47):30915-20. [PubMed:9812985 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23